

Key Investor Information

This document provides you with key investor information about this Sub-Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Sub-Fund. You are advised to read it so you can make an informed decision about whether to invest.

AMUNDI S&P GLOBAL HEALTH CARE ESG UCITS ETF DR - EUR A Sub-Fund of AMUNDI ETF ICAV

ISIN codes: (A) IE0006FM6MI8, (D) IE000JKS50V3

This ICAV has appointed Amundi Ireland Limited, an entity part of Amundi group, as its Management Company

Objectives and Investment Policy

This Sub-Fund is passively managed.

The Sub-Fund is a financial product that promotes among other characteristics ESG characteristics pursuant to Article 8 of the Disclosure Regulation.

The objective of this Sub-Fund is to track the performance of S&P Developed Ex-Korea LargeMidCap Sustainability Enhanced Health Care Index (the "Index"), and to minimize the tracking error between the net asset value of the Sub-Fund and the performance of the Index. The Sub-Fund aims to achieve a level of tracking error of the Sub-Fund and its Index that will not normally exceed 1%.

The Index is a net total return index, meaning that dividends net of tax paid by the index constituents are included in the Index return.

The Index is an equity index that measures the performance of eligible equity securities from the S&P Developed Ex-Korea LargeMidCap Health Care index (the "Parent Index"). The Parent Index is designed to measure the performance of large and mid-cap health care companies in developed markets excluding Korea which make up approximately 85% of the total available capital. Health care companies are identified by reference to the GICS. The health care sector includes health care providers and services, companies that manufacture and distribute health care equipment and supplies, and health care technology companies. It also includes companies involved in the research, development, production and marketing of pharmaceuticals and biotechnology products. The Index is selected and weighted to enhance Sustainability and ESG profiles, meet environmental targets, and reduce carbon footprint, all compared to the Parent Index.

Information on how the Index is consistent with environmental, social and governance characteristics is available in the prospectus.

More information about the composition of the Index and its operating rules are available in the prospectus and at: eu.spindices.com

The Index value is available via Bloomberg (SPDSEHUN).


The Sub-Fund integrates sustainability risks as outlined in more detail in section "Sustainable Investment" of the prospectus.

Dividend Policy : the accumulation share automatically retains, and re-invests, net investment incomes within the Sub-Fund when the distribution share pays dividends annually.

The minimum recommended holding term is 5 years.

The Sub-Fund's shares are listed and traded on one or more stock exchanges. In normal circumstances, you may deal in shares during the trading hours of the stock exchanges, provided that the Market Makers can maintain market liquidity. Only authorised participants (e.g. selected financial institutions) may deal in shares directly with the Sub-Fund on the primary market. Further details are provided in the prospectus of the ICAV.

Risk and Reward Profile



The risk level of this Sub-Fund mainly reflects the market risk arising from investments in equities of the industry sector the Sub-Fund invests in.

Historical data may not be a reliable indication for the future.

Risk category shown is not guaranteed and may shift over time.

The lowest category does not mean 'risk free'.

Your initial investment does not benefit from any guarantee or protection.

Important risks materially relevant to the Sub-Fund which are not adequately captured by the indicator:

- Liquidity risk: in case of low trading volume on financial markets, any buy or sell trade on these markets may lead to important market variations/fluctuations that may impact your portfolio valuation.
 - Counterparty risk: represents the risk of default of a market participant to fulfil its contractual obligations vis-à-vis your portfolio.
 - Operational risk: this is the risk of default or error within the different service providers involved in managing and valuing your portfolio.
- The occurrence of any of these risks may have an impact on the net asset value of your portfolio.

Charges

The charges you pay are used to pay the costs of running the Sub-Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest	
Entry charge*	3.00%
Exit charge*	3.00%
Conversion charge	Not applicable
This is the maximum that might be taken out of your money before the proceeds of your investment are paid out.	
Charges taken from the Sub-Fund over a year	
Ongoing charges	0.18%
Charges taken from the Sub-Fund under certain specific conditions	
Performance fee	None

* Entry and exit charges will only apply when shares are subscribed or redeemed directly from the Sub-Fund, and will not apply when investors buy or sell such shares on stock exchanges. Investors dealing on exchange will pay fees charged by their intermediaries. Such charges can be obtained from intermediaries.

For more information about charges, please see charges paragraph of the prospectus of the UCITS, which is available at: amundi.ie

The **entry**, **exit** and **conversion charges** shown are maximum figures applied on the primary market only. In some cases you might pay less - you can find this out from your financial adviser.

The **ongoing charges** figure is based on expenses for the current year. This figure may vary from year to year. It excludes:

- Performance fees
- Portfolio transaction costs, except in the case of an entry/exit charge paid by the Sub-Fund when buying or selling units in another collective investment undertaking.

The ongoing charges displayed are estimated. For each accounting period, the Sub-Fund's annual report will display the exact amount.

Past Performance

The Sub-Fund does not yet have performance data for one complete calendar year to display a graph of past performance.

The chart has a limited value as a guide to future performance.

Sub-Fund launch: 2022.

Share class launch: 2022.

The reference currency is the Euro.

The reference Index is : S&P Developed Ex-Korea LargeMidCap Sustainability Enhanced Health Care Index

Practical Information

- Name of the depositary: HSBC Continental Europe.
- Further information about the ICAV (prospectus, periodical reports) can be obtained in English, free of charge, at the following address: Amundi Ireland Limited, 1 George's Quay Plaza, Georges Quay, Dublin 2, Ireland.
- The details of the up-to-date remuneration policy, including, but not limited to, a description of how remuneration and benefits are calculated, the identity of persons responsible for awarding the remuneration and benefits are available by means of the following website: <https://www.amundi.ie> and a paper copy will be made available free of charge upon request.
- Other practical information (e.g. latest net asset value, transparency policy and information about the asset composition of the Sub-Fund) can be obtained on the internet site amundi.ie or amundi.tcf.com.
- Indicative net asset value is published by the relevant stock exchanges.
- The ICAV contains a large number of other Sub-Funds and other classes which are described in the prospectus. Conversion into shares of another Sub-Fund of the ICAV may be made, subject to the conditions of the prospectus.
- Each Sub-Fund corresponds to a distinct part of the assets and liabilities of the ICAV. As a consequence, the assets of each Sub-Fund are exclusively available to satisfy the rights of investors in relation to that Sub-Fund and the right of creditors whose claims have arisen in connection with the creation, the operation or the liquidation of that Sub-Fund.
- This document describes a Sub-Fund of the ICAV. The prospectus and periodical reports are prepared for the entire ICAV named at the beginning of this document.
- The ICAV is subject to Irish taxation legislation which may have an adverse impact on the personal tax of the investor.
- Amundi Ireland Limited may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the ICAV.

This ICAV is authorised in Ireland and regulated by the Central Bank of Ireland.

Amundi Ireland Limited is authorised and regulated by the Central Bank of Ireland.

This key investor information is accurate as at July 18, 2022.